Compare American Well Corp (AMWL) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Well Corp vs Invesco Ltd. — how do they compare? American Well Corp trades at $9.89 (market cap $165.58M), while Invesco Ltd. trades at $28.79 (market cap $12.85B). The key difference: Invesco Ltd. is far larger — about 77.6× American Well Corp's market cap, and Invesco Ltd. pays a 2.97% dividend while American Well Corp pays none. Which is the better fit depends on your goals.
| AMWL | IVZ | |
|---|---|---|
Market Cap | $165.58M | $12.85B |
Sector | Health | Financials |
52-Week High | $9.91 | $29.44 |
52-Week Low | $3.78 | $16.74 |
Enterprise Value | -$9.66M | $23.09B |
Dividend Yield | — | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMWL trades at $9.91, up 8.66% today, with bullish technical signals and positive momentum. The company shows improving financial trends with declining losses and strong gross margins of 52.9%, though it remains unprofitable with a -37.02% net margin. Recent news highlights Amazon's appointment of Amwell's co-founder to lead its healthcare unit, signaling industry validation.
While AMWL shows operational improvement and attractive valuation multiples (P/S 0.68, P/B 0.73), the stock faces headwinds from persistent losses and negative cash flow. Analyst consensus is cautious with a $7.25 price target below current levels, suggesting limited near-term upside despite recent positive momentum.
IVZ trades at $28.98, up 1.29% today, with a bullish technical signal and analyst consensus price target of $29.79. Recent earnings show mixed results, beating in Q3 and Q4 2025 but missing in Q1 2026, while the company reported a net loss of $281.70 million in 2025. Positive cash flow from operations of $1.53 billion and a recent dividend payment of $0.22 per share highlight financial stability amid profitability challenges.
The outlook for IVZ is cautiously optimistic, supported by strong analyst buy ratings and improving assets under management, but weighed down by negative net income margins and competitive pressures in asset management. Key risks include execution on profitability and market volatility affecting AUM growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Well Corp
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
